Lowey Dannenberg served as class counsel in a generic pay-for-delay case against GlaxoSmithKline and Valeant (f/k/a Biovail), alleging they formed an anti-competitive agreement to prevent the market entry of a cheaper, generic version of the blockbuster antidepressant drug, Wellbutrin XL.

Lowey achieved a $11.75 settlement with Valeant.

In re Wellbutrin XL Antitrust Litig., Case No. 08 Civ. 2433 (E.D. Pa.)